Use of Pharmacokinetic/Pharmacodynamic Biomarkers to Support Rational Cancer Drug Development

• Workman P : Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics.Cold Spring Harb. Symp. Quant. Biol.70 , 499–515 (2005).
   PubMedGoogle Scholar
• Hanahan D , WeinbergRA: The hallmarks of cancer.Cell100(1), 57–70 (2000).
   PubMed Web of Science ®Google Scholar
• Collins I , WorkmanP: New approaches to molecular cancer therapeutics.Nat. Chem. Biol.2(12), 689–700 (2006).
   PubMed Web of Science ®Google Scholar
• Workman P : Genomics and the second golden era of cancer drug development.Mol. Biosyst.1(1), 17–26 (2005).
   PubMedGoogle Scholar
• Kelloff GJ , SigmanCC: New science-based endpoints to accelerate oncology drug development.Eur. J. Cancer41(4), 491–501 (2005).
   PubMed Web of Science ®Google Scholar
• Reichert JM : Trends in development and approval times for new therapeutics in the United States.Nat. Rev. Drug Discov.2(9), 695–702 (2003).
   PubMed Web of Science ®Google Scholar
• Kola I , LandisJ: Can the pharmaceutical industry reduce attrition rates?Nat. Rev. Drug Discov.3(8), 711–715 (2004).
   PubMed Web of Science ®Google Scholar
• Workman P : Challenges of PK/PD measurements in modern drug development.Eur. J. Cancer38(16), 2189–2193 (2002).
   PubMed Web of Science ®Google Scholar
• Workman P : How much gets there and what does it do? The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development.Curr. Pharm. Des.9(11), 891–902 (2003).
   PubMed Web of Science ®Google Scholar
• Biomarkers Definitions Working Group: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther.69 , 89–95 (2001).
   PubMed Web of Science ®Google Scholar
• Frank R , HargreavesR: Clinical biomarkers in drug discovery and development.Nat. Rev. Drug Discov.2(7), 566–580 (2003).
   PubMed Web of Science ®Google Scholar
• Ludwig JA , WeinsteinJN: Biomarkers in cancer staging, prognosis and treatment selection.Nat. Rev. Cancer5(11), 845–856 (2005).
   PubMed Web of Science ®Google Scholar
• Bubley GJ , CarducciM, DahutW et al.: Eligibility and response guidelines for Phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J. Clin. Oncol.17(11), 3461–3467 (1999).
   PubMed Web of Science ®Google Scholar
• Rustin GJ , BastRCJr, KelloffGJet al.: Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin. Cancer Res.10(11), 3919–3926 (2004).
   PubMed Web of Science ®Google Scholar
• Slamon DJ , ClarkGM, WongSG, LevinWJ, UllrichA, McGuireWL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science235(4785), 177–182 (1987).
   PubMed Web of Science ®Google Scholar
• Baselga J , AlbanellJ, RuizAet al.: Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J. Clin. Oncol.23(23), 5323–5333 (2005).
   PubMed Web of Science ®Google Scholar
• Clarke PA , HosteinI, BanerjiUet al.: Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the Hsp90 molecular chaperone. Oncogene19(36), 4125–4133 (2000).
   PubMed Web of Science ®Google Scholar
• Dowsett M , SmithIE, EbbsSRet al.: Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin. Cancer Res.12(Suppl. 3 Pt 2) , S1024–S1030 (2006).
   PubMed Web of Science ®Google Scholar
• Workman P: Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. Mol. Cancer Ther.2(2), 131–138 (2003).
   PubMed Web of Science ®Google Scholar
• Park JW , KerbelRS, KelloffGJet al.: Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin. Cancer Res.10(11), 3885–3896 (2004).
   PubMed Web of Science ®Google Scholar
• Workman P: The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones. Cancer Chemother. Pharmacol.52(Suppl. 1) , S45–S56 (2003).
   PubMed Web of Science ®Google Scholar
• Sarker D , WorkmanP: Pharmacodynamic biomarkers for molecular cancer therapeutics.Adv. Cancer Res.96 , 213–268 (2007).
   PubMed Web of Science ®Google Scholar
• Clarke PA , te PoeleR, WorkmanP: Gene expression microarray technologies in the development of new therapeutic agents. Eur. J. Cancer40(17), 2560–2591 (2004).
   PubMed Web of Science ®Google Scholar
• Sears C , ArmstrongSA: Microarrays to identify new therapeutic strategies for cancer.Adv. Cancer Res.96 , 51–74 (2007).
   PubMed Web of Science ®Google Scholar
• Clarke PA , te PoeleR, WoosterR, WorkmanP: Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential. Biochem. Pharmacol.62(10), 1311–1336 (2001).
   PubMed Web of Science ®Google Scholar
• Clarke PA , GeorgeML, EasdaleSet al.: Molecular pharmacology of cancer therapy in human colorectal cancer by gene expression profiling. Cancer Res.63(20), 6855–6863 (2003).
   PubMed Web of Science ®Google Scholar
• van de Vijver MJ , HeYD, van‘t VeerLJet al.: A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med.347(25), 1999–2009 (2002).
   PubMed Web of Science ®Google Scholar
• Petricoin EF , ArdekaniAM, HittBAet al.: Use of proteomic patterns in serum to identify ovarian cancer. Lancet359(9306), 572–577 (2002).
   PubMed Web of Science ®Google Scholar
• Check E : Proteomics and cancer: running before we can walk?Nature429(6991), 496–497 (2004).
   PubMed Web of Science ®Google Scholar
• Ransohoff DF : Lessons from controversy: ovarian cancer screening and serum proteomics.J. Natl Cancer Inst.97(4), 315–319 (2005).
   PubMedGoogle Scholar
• Carr KM , RosenblattK, PetricoinEF, LiottaLA: Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy. Hum. Genomics1(2), 134–140 (2004).
   PubMedGoogle Scholar
• Chung CH , LevyS, ChaurandP, CarboneDP: Genomics and proteomics: emerging technologies in clinical cancer research. Crit. Rev. Oncol. Hematol.61(1), 1–25 (2007).
   PubMed Web of Science ®Google Scholar
• Panaretou B , SiligardiG, MeyerPet al.: Activation of the ATPase activity of Hsp90 by the stress-regulated cochaperone aha1. Mol.Cell10(6), 1307–1318 (2002).
   PubMed Web of Science ®Google Scholar
• Maloney A , ClarkePA, Naaby-HansenSet al.: Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res.67(7), 3239–3253 (2007).
   PubMed Web of Science ®Google Scholar
• Cristofanilli M , BuddGT, EllisMJet al.: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med.351(8), 781–791 (2004).
   PubMed Web of Science ®Google Scholar
• Hayes DF , CristofanilliM, BuddGTet al.: Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin. Cancer Res.12(14 Pt 1) , 4218–4224 (2006).
   PubMed Web of Science ®Google Scholar
• Bertolini F , ShakedY, MancusoP, KerbelRS: The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat. Rev. Cancer6(11), 835–845 (2006).
   PubMed Web of Science ®Google Scholar
• Eary JF , MankoffDA, SpenceAMet al.: 2-[C-11]thymidine imaging of malignant brain tumors. Cancer Res.59(3), 615–621 (1999).
   PubMed Web of Science ®Google Scholar
• Shields AF , GriersonJR, DohmenBMet al.: Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat. Med.4(11), 1334–1336 (1998).
   PubMed Web of Science ®Google Scholar
• Findlay M , YoungH, CunninghamDet al.: Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J. Clin. Oncol.14(3), 700–708 (1996).
   PubMed Web of Science ®Google Scholar
• Keen HG , DekkerBA, DisleyLet al.: Imaging apoptosis in vivo using 124I-annexin V and PET. Nucl. Med. Biol.32(4), 395–402 (2005).
   PubMed Web of Science ®Google Scholar
• Galbraith SM , RustinGJ, LodgeMAet al.: Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J. Clin. Oncol.20(18), 3826–3840 (2002).
   PubMed Web of Science ®Google Scholar
• Stroobants S , GoeminneJ, SeegersMet al.: 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur. J. Cancer39(14), 2012–2020 (2003).
   PubMed Web of Science ®Google Scholar
• Demetri GD , vonMM, BlankeCDet al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med.347(7), 472–480 (2002).
   PubMed Web of Science ®Google Scholar
• Workman P , AboagyeEO, ChungYLet al.: Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J. Natl Cancer Inst.98(9), 580–598 (2006).
   PubMedGoogle Scholar
• Pearson H : Meet the human metabolome.Nature446(7131), 8 (2007).
   PubMed Web of Science ®Google Scholar
• Wishart DS , TzurD, KnoxCet al.: HMDB: the Human Metabolome Database. Nucleic Acids Res.35(Database issue) , D521–D526 (2007).
   PubMed Web of Science ®Google Scholar
• Clayton TA , LindonJC, CloarecOet al.: Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature440(7087), 1073–1077 (2006).
   PubMed Web of Science ®Google Scholar
• Evans WE , RellingMV: Clinical pharmacokinetics–pharmacodynamics of anticancer drugs.Clin. Pharmacokinet.16(6), 327–336 (1989).
   PubMed Web of Science ®Google Scholar
• Raynaud FI , WhittakerSR, FischerPMet al.: In vitro and in vivo pharmacokinetics–pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin. Cancer Res.11(13), 4875–4887 (2005).
   PubMed Web of Science ®Google Scholar
• Benson C , WhiteJ, DeBJet al.: A Phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br. J. Cancer96(1), 29–37 (2007).
   PubMed Web of Science ®Google Scholar
• Meibohm B , DerendorfH: Pharmacokinetic/pharmacodynamic studies in drug product development.J. Pharm. Sci.91(1), 18–31 (2002).
   PubMed Web of Science ®Google Scholar
• Luo FR , YangZ, CamusoAet al.: Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin. Cancer Res.12(23), 7180–7186 (2006).
   PubMed Web of Science ®Google Scholar
• Luo FR , YangZ, DongHet al.: Prediction of active drug plasma concentrations achieved in cancer patients by pharmacodynamic biomarkers identified from the geo human colon carcinoma xenograft model. Clin. Cancer Res.11(15), 5558–5565 (2005).
   PubMed Web of Science ®Google Scholar
• Bader AG , KangS, ZhaoL, VogtPK: Oncogenic PI3K deregulates transcription and translation.Nat. Rev. Cancer5(12), 921–929 (2005).
   PubMed Web of Science ®Google Scholar
• Vivanco I , SawyersCL: The phosphatidylinositol 3-kinase AKT pathway in human cancer.Nat. Rev. Cancer2(7), 489–501 (2002).
   PubMed Web of Science ®Google Scholar
• Adjei AA , HidalgoM: Intracellular signal transduction pathway proteins as targets for cancer therapy.J. Clin. Oncol.23(23), 5386–5403 (2005).
   PubMed Web of Science ®Google Scholar
• Campbell IG , RussellSE, ChoongDYet al.: Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res.64(21), 7678–7681 (2004).
   PubMed Web of Science ®Google Scholar
• Broderick DK , DiC, ParrettTJet al.: Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res.64(15), 5048–5050 (2004).
   PubMed Web of Science ®Google Scholar
• Samuels Y , WangZ, BardelliAet al.: High frequency of mutations of the PIK3CA gene in human cancers. Science304(5670), 554 (2004).
   PubMed Web of Science ®Google Scholar
• Kang S , BaderAG, VogtPK: Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.Proc. Natl Acad. Sci. USA102(3), 802–807 (2005).
   PubMed Web of Science ®Google Scholar
• Schmelzle T , HallMN: TOR, a central controller of cell growth.Cell103(2), 253–262 (2000).
   PubMed Web of Science ®Google Scholar
• Cantley LC , NeelBG: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway.Proc. Natl Acad. Sci. USA96(8), 4240–4245 (1999).
   PubMed Web of Science ®Google Scholar
• Cully M , YouH, LevineAJ, MakTW: Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis.Nat. Rev. Cancer6(3), 184–192 (2006).
   PubMed Web of Science ®Google Scholar
• Ringel MD , HayreN, SaitoJet al.: Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res.61(16), 6105–6111 (2001).
   PubMed Web of Science ®Google Scholar
• Sordella R , BellDW, HaberDA, SettlemanJ: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science305(5687), 1163–1167 (2004).
   PubMed Web of Science ®Google Scholar
• Sun M , WangG, PacigaJEet al.: AKT1/PKBα kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am. J. Pathol.159(2), 431–437 (2001).
   PubMed Web of Science ®Google Scholar
• Hennessy BT , SmithDL, RamPT, LuY, MillsGB: Exploiting the PI3K/AKT pathway for cancer drug discovery.Nat. Rev. Drug Discov.4(12), 988–1004 (2005).
   PubMed Web of Science ®Google Scholar
• Workman P: Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. Biochem. Soc. Trans.32(Pt 2) , 393–396 (2004).
   PubMed Web of Science ®Google Scholar
• Faivre S , KroemerG, RaymondE: Current development of mTOR inhibitors as anticancer agents.Nat. Rev. Drug Discov.5(8), 671–688 (2006).
   PubMed Web of Science ®Google Scholar
• Huang S , BjornstiMA, HoughtonPJ: Rapamycins: mechanism of action and cellular resistance.Cancer Biol. Ther.2(3), 222–232 (2003).
   PubMed Web of Science ®Google Scholar
• Hudes G , CarducciM, TomczakPet al.: Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N. Engl. J. Med.356(22), 2271–2281 (2007).
   PubMed Web of Science ®Google Scholar
• Galanis E , BucknerJC, MaurerMJet al.: Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol.23(23), 5294–5304 (2005).
   PubMed Web of Science ®Google Scholar
• Chan S , ScheulenME, JohnstonSet al.: Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J. Clin. Oncol.23(23), 5314–5322 (2005).
   PubMed Web of Science ®Google Scholar
• Hidalgo M : New target, new drug, old paradigm.J. Clin. Oncol.22(12), 2270–2272 (2004).
   PubMed Web of Science ®Google Scholar
• Sawyers CL : Will mTOR inhibitors make it as cancer drugs?Cancer Cell4(5), 343–348 (2003).
   PubMed Web of Science ®Google Scholar
• Dudkin L , DillingMB, CheshirePJet al.: Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin. Cancer Res.7(6), 1758–1764 (2001).
   PubMed Web of Science ®Google Scholar
• Peralba JM , DeGraffenriedL, FriedrichsWet al.: Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin. Cancer Res.9(8), 2887–2892 (2003).
   PubMed Web of Science ®Google Scholar
• Atkins MB , HidalgoM, StadlerWMet al.: Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol.22(5), 909–918 (2004).
   PubMed Web of Science ®Google Scholar
• Boulay A , Zumstein-MeckerS, StephanCet al.: Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res.64(1), 252–261 (2004).
   PubMed Web of Science ®Google Scholar
• O´Donnell A , FaivreS, JudsonIet al.: A Phase I study of the oral mTOR inhibitor RAD001 as monotherapy to identify the optimal biologically effective dose using toxicity, pharmacokinetic (PK) and pharmacodynamic (PD) endpoints in patients with solid tumours. Proc. Am. Soc. Clin. Oncol.22 (Abstract 803) (2003).
   Google Scholar
• Tabernero J , RojoF, BurrisHet al.: A Phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor everolimus (RAD001) in patients (pts) with advanced solid tumors. J. Clin. Oncol.23(16), S193 (2005).
   Google Scholar
• O‘Reilly KE , RojoF, SheQBet al.: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res.66(3), 1500–1508 (2006).
   PubMed Web of Science ®Google Scholar
• Fan QW , KnightZA, GoldenbergDDet al.: A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell9(5), 341–349 (2006).
   PubMed Web of Science ®Google Scholar
• Raynaud FI , EcclesS, ClarkePAet al.: Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res.67(12), 5840–5850 (2007).
   PubMed Web of Science ®Google Scholar
• Thomas GV , TranC, MellinghoffIKet al.: Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med.12(1), 122–127 (2006).
   PubMed Web of Science ®Google Scholar
• Thompson JE , ThompsonCB: Putting the rap on Akt.J. Clin. Oncol.22(20), 4217–4226 (2004).
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK , SawyersCL: TORward AKTually useful mouse models.Nat. Med.10(6), 579–580 (2004).
   PubMed Web of Science ®Google Scholar
• Hayakawa M , KaizawaH, MoritomoHet al.: Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110α inhibitors. Bioorg. Med. Chem.14(20), 6847–6858 (2006).
   PubMed Web of Science ®Google Scholar
• Hayakawa M , KaizawaH, KawaguchiKet al.: Synthesis and biological evaluation of imidazo[1,2-α]pyridine derivatives as novel PI3 kinase p110α inhibitors. Bioorg. Med. Chem.15(1), 403–412 (2007).
   PubMed Web of Science ®Google Scholar
• Workman P , ClarkePA, GuillardS, RaynaudFI: Drugging the PI3 kinome.Nat. Biotechnol.24(7), 794–796 (2006).
   PubMed Web of Science ®Google Scholar
• Workman P: Drugging the cancer kinome: successes, problems, and emerging solutions. In: ASCO Educational Book 2005. Parry MC (Ed.). American Society of Clinical Oncology, 950–960 (2005).
   Google Scholar
• Knight ZA , GonzalezB, FeldmanMEet al.: A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell125(4), 733–747 (2006).
   PubMed Web of Science ®Google Scholar
• Beloueche-Babari M , JacksonLE, Al-SaffarNMet al.: Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells. Mol. Cancer Ther.5(1), 187–196 (2006).
   PubMed Web of Science ®Google Scholar
• Beloueche-Babari M , JacksonLE, Al-SaffarNM, WorkmanP, LeachMO, RonenSM: Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition. Cancer Res.65(8), 3356–3363 (2005).
   PubMed Web of Science ®Google Scholar
• Ihle NT , WilliamsR, ChowSet al.: Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol. Cancer Ther.3(7), 763–772 (2004).
   PubMed Web of Science ®Google Scholar
• Williams R , BakerAF, IhleNT, WinklerAR, KirkpatrickL, PowisG: The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling. Cancer Chemother. Pharmacol.58(4), 444–450 (2006).
   PubMed Web of Science ®Google Scholar
• Powers MV , WorkmanP: Targeting of multiple signaling pathways by heat shock protein 90 molecular chaperone inhibitors.Endocr. Relat. Cancer13(Suppl. 1) , S125–S135 (2006).
   PubMed Web of Science ®Google Scholar
• Whitesell L , LindquistSL: Hsp90 and the chaperoning of cancer.Nat. Rev. Cancer5(10), 761–772 (2005).
   PubMed Web of Science ®Google Scholar
• Maloney A , WorkmanP: Hsp90 as a new therapeutic target for cancer therapy: the story unfolds.Expert Opin. Biol. Ther.2(1), 3–24 (2002).
   PubMed Web of Science ®Google Scholar
• Workman P: Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett.206(2), 149–157 (2004).
   PubMed Web of Science ®Google Scholar
• Banerji U , O‘DonnellA, ScurrMet al.: Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J. Clin. Oncol.23(18), 4152–4161 (2005).
   PubMed Web of Science ®Google Scholar
• Goetz MP , ToftD, ReidJet al.: Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J. Clin. Oncol.23(6), 1078–1087 (2005).
   PubMed Web of Science ®Google Scholar
• Grem JL , MorrisonG, GuoXDet al.: Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J. Clin. Oncol.23(9), 1885–1893 (2005).
   PubMed Web of Science ®Google Scholar
• Nowakowski GS , McCollumAK, AmesMMet al.: A Phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin. Cancer Res.12(20 Pt 1) , 6087–6093 (2006).
   PubMed Web of Science ®Google Scholar
• Ramanathan RK , TrumpDL, EisemanJLet al.: Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin. Cancer Res.11(9), 3385–3391 (2005).
   PubMed Web of Science ®Google Scholar
• Banerji U , WaltonM, RaynaudFet al.: Pharmacokinetic–pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin. Cancer Res.11(19 Pt 1) , 7023–7032 (2005).
   PubMed Web of Science ®Google Scholar
• Maloney A , ClarkePA, WorkmanP: Genes and proteins governing the cellular sensitivity to Hsp90 inhibitors: a mechanistic perspective.Curr.Cancer Drug Targets3(5), 331–341 (2003).
   PubMed Web of Science ®Google Scholar
• Maloney A , ClarkePA: Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxy geldanamycin.Cancer Res.67(7), 3239–3253 (2007).
   PubMed Web of Science ®Google Scholar
• Hostein I , RobertsonD, DiStefanoF, WorkmanP, ClarkePA: Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis.Cancer Res.61(10), 4003–4009 (2001).
   PubMed Web of Science ®Google Scholar
• Grbovic OM , BassoAD, SawaiAet al.: V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc. Natl Acad. Sci. USA103(1), 57–62 (2006).
   PubMed Web of Science ®Google Scholar
• da Rocha DS , FriedlosF, LightY, SpringerC, WorkmanP, MaraisR: Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res.65(23), 10686–10691 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang H , ChungD, YangYCet al.: Identification of new biomarkers for clinical trials of Hsp90 inhibitors. Mol. Cancer Ther.5(5), 1256–1264 (2006).
   PubMed Web of Science ®Google Scholar
• Chung YL , TroyH, BanerjiUet al.: Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models. J. Natl Cancer Inst.95(21), 1624–1633 (2003).
   PubMedGoogle Scholar
• Liu D , HutchinsonOC, OsmanS, PriceP, WorkmanP, AboagyeEO: Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin.Br. J. Cancer87(7), 783–789 (2002).
   PubMed Web of Science ®Google Scholar
• Weber WA : Chaperoning drug development with PET.J. Nucl. Med.47(5), 735–737 (2006).
   PubMed Web of Science ®Google Scholar
• Smith-Jones PM , SolitDB, AkhurstT, AfrozeF, RosenN, LarsonSM: Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors.Nat. Biotechnol.22(6), 701–706 (2004).
   PubMed Web of Science ®Google Scholar
• Smith-Jones PM , SolitD, AfrozeF, RosenN, LarsonSM: Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J. Nucl. Med.47(5), 793–796 (2006).
   PubMed Web of Science ®Google Scholar
• Parulekar WR , EisenhauerEA: Novel endpoints and design of early clinical trials.Ann. Oncol.13(Suppl. 4) , 139–143 (2002).
   PubMed Web of Science ®Google Scholar
• Parulekar WR , EisenhauerEA: Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice.J. Natl Cancer Inst.96(13), 990–997 (2004).
   PubMed Web of Science ®Google Scholar
• Stiles T , GrantV, MawbeyN: British Association of Research Quality Assurance: Good Clinical Laboratory Practice (GCLP). (2005).
   Google Scholar
• Miller KJ , BowsherRR, CelnikerAet al.: Workshop on bioanalytical methods validation for macromolecules: summary report. Pharm. Res.18(9), 1373–1383 (2001).
   PubMed Web of Science ®Google Scholar
• Swanson BN : Delivery of high-quality biomarker assays.Dis. Markers.18(2), 47–56 (2002).
   PubMed Web of Science ®Google Scholar
• Lee JW , WeinerRS, SailstadJMet al.: Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm. Res.22(4), 499–511 (2005).
   PubMed Web of Science ®Google Scholar
• Cummings J , WardTH, LacasseEet al.: Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br. J. Cancer92(3), 532–538 (2005).
   PubMed Web of Science ®Google Scholar
• Lee JW , FigeysD, VasilescuJ: Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.Adv. Cancer Res.96 , 269–298 (2007).
   PubMed Web of Science ®Google Scholar
• Hardcastle A , BoxallK, RichardsJet al.: Solid-phase immunoassays in mechanism-based drug discovery: their application in the development of inhibitors of the molecular chaperone heat-shock protein 90. Assay Drug Dev. Technol.3(3), 273–285 (2005).
   PubMed Web of Science ®Google Scholar
• Gowan SM , HardcastleA, HallsworthAEet al.: Application of meso scale technology for the measurement of phosphoproteins in human tumor xenografts. Assay Drug Dev. Technol.5(3), 391–402 (2007).
   PubMed Web of Science ®Google Scholar
• Kelloff GJ , BastRCJr, CoffeyDSet al.: Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clin. Cancer Res.10(11), 3881–3884 (2004).
   PubMed Web of Science ®Google Scholar
• Kummar S , KindersR, RubinsteinLet al.: Compressing drug development timelines in oncology using phase ’0‘ trials. Nat. Rev. Cancer7(2), 131–139 (2007).
   PubMed Web of Science ®Google Scholar

Website

• Human Metabolome Database www.hmdb.ca
   Google Scholar